Changchun GeneScience Pharmaceutical

Privately held: no public share price

Assets

(1 total)
1Total Assets
0Approved
1Phase 3 / Filed
0Phase 1–2 / Early
1Diseases
Showing 1 of 1 assets
Target & Modality
Phase 3
Growth hormone receptorBiologic (subtype unspecified)
Chronic Kidney Disease

Upcoming events

No upcoming trial completions or earnings dates on record for this company's assets.

Financial reports

Annual history (2 years)

PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2024-FY$1.5B———report ↗
View 1 more year
PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2023-FY$1.6B———report ↗